Sign in Subscribe
Cancer

Gastric Cancer Study Reveals Optimal Medication Regimen for Early Diagnosis and Treatment Prevention

Strategic Insights

— 1 min read

Research conducted by investigators at Zunyi Medical University in Guizhou, People's Republic of China, has led to a significant breakthrough in the early diagnosis and treatment of gastric cancer. By examining the effectiveness of various medications on gastric mucosal cleansing quality in patients infected with H. pylori, the study aimed to identify the optimal regimen for early gastric cancer screening. The study involved 264 patients, who were randomly assigned to six different treatment groups, each receiving a unique combination of medications.

Key Takeaways:

  • The study found that a combination of simethicone, pronase, and sodium bicarbonate significantly improved the quality of gastric mucosal cleansing, leading to a higher detection rate of gastric cancer, polyps, and adenomas.
  • The implementation of the study's results and their inclusion in guidelines may reduce economic expenditures by minimizing the need for social and healthcare services.
  • The study's findings have the potential to improve the quality of life for patients with gastric cancer by enabling early diagnosis and treatment.
  • The research was supported by the National Natural Science Foundation of China.
  • The study's authors include Jingyu Xu, Xinyi Mu, Yi Fan, and Rui Xie from Zunyi Medical University.
  • The study was published in Frontiers in Medicine and is available online.

Statistics:

  • 264 patients were enrolled in the study, representing a diverse patient population.
  • The study involved six different treatment groups, each with 44 patients.
  • The primary endpoint was the gastric mucosa cleanliness score, which was significantly improved in the group receiving simethicone, pronase, and sodium bicarbonate.
  • The detection rate of gastric cancer, polyps, and adenomas was significantly higher in the group receiving the combination of medications.
  • The study's results have the potential to reduce economic expenditures by minimizing social and healthcare services.

Sources:

  • Xu, J., Mu, X., Fan, Y., & Xie, R. (2025). Exploration of the Optimal Regimen of Gastric Mucosal Cleansing Medication for the h. Pylori Population Before Me-nbi Screening: Study Protocol for a Single-center, Single-blind, Randomized Controlled Trial. Frontiers in Medicine, 12.
  • NewsRx. (2025). New Gastric Cancer Study Results from Zunyi Medical University Described (Exploration of the Optimal Regimen of Gastric Mucosal Cleansing Medication for the h. Pylori Population Before Me-nbi Screening: Study Protocol for a ...). Cancer Weekly, p 669.

Read more